Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “hold” rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued on Tuesday.

Other equities research analysts also recently issued research reports about the stock. Laidlaw reissued a “hold” rating and set a $119.00 price objective (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 1st. Cowen and Company reissued an “outperform” rating and set a $232.00 price objective on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. BMO Capital Markets increased their price objective on shares of Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 1st. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, Cantor Fitzgerald reissued an “underweight” rating and set a $69.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $164.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The firm had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter in the prior year, the firm earned ($3.14) earnings per share. The business’s quarterly revenue was up 459.6% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: “Intercept Pharmaceuticals’ (ICPT) Hold Rating Reaffirmed at Needham & Company LLC” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/26/intercept-pharmaceuticals-icpt-hold-rating-reaffirmed-at-needham-company-llc.html.

In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 217 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the completion of the sale, the director now owns 3,710 shares in the company, valued at $470,279.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO David Shapiro sold 553 shares of the stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $124.01, for a total transaction of $68,577.53. Following the completion of the sale, the chief marketing officer now owns 44,562 shares of the company’s stock, valued at approximately $5,526,133.62. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,013 shares of company stock valued at $966,747. Corporate insiders own 4.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its stake in Intercept Pharmaceuticals by 100.0% in the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after acquiring an additional 15,000 shares during the last quarter. Oppenheimer & Co. Inc. lifted its stake in Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 178 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Intercept Pharmaceuticals in the first quarter valued at $414,000. Geode Capital Management LLC lifted its stake in Intercept Pharmaceuticals by 12.8% in the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after acquiring an additional 16,392 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in Intercept Pharmaceuticals by 9.2% in the first quarter. Van ECK Associates Corp now owns 25,550 shares of the biopharmaceutical company’s stock valued at $2,890,000 after acquiring an additional 2,161 shares during the last quarter. Hedge funds and other institutional investors own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.